Table 1 Mutant P53 , P16 , and Smad4 expression in relation to clinicopathological parameters ( n = 120)

Age ≤60 year

26 (35.6%)

47 (64.4%)

0.766

34 (46.6%)

39 (53.4%)

0.666

47 (64.4%)

26 (35.6%)

0.595

Age >60 year

18 (38.3%)

29 (61.7%)

20 (42.6%)

27 (57.4%)

28 (59.6%)

19 (40.4%)

Male

25 (43.1%)

33 (56.9%)

0.157

27 (46.6%)

31 (53.4%)

0.741

32 (55.2%)

26 (44.8%)

0.109

Female

19 (30.6%)

43 (69.4%)

27 (43.5%)

35 (56.5%)

43 (69.4%)

19 (30.6%)

Tumor size (cm)

 T1 (≤3)

14 (58.3%)

10 (41.7%)

0.041

8 (33.3%)

16 (66.7%)

0.392

11 (45.8%)

13 (54.2%)

0.033

 T2 (>3 ≤ 7)

24 (32.9%)

49 (67.1%)

34 (46.6%)

39 (53.4%)

45 (61.6%)

28 (38.4%)

 T3/4 (>7)

6 (26.1%)

17 (73.9%)

12 (52.2%)

11 (47.8%)

19 (82.6%)

4 (17.4%)

Lymph nodes

 Negative

27 (38.0%)

44 (62.0%)

0.709

23 (32.4%)

48 (67.6%)

0.001

38 (53.5%)

33 (46.5%)

0.014

 Positive

17 (34.7%)

32 (65.3%)

31 (63.3%)

18 (36.7%)

37 (75.5%)

12 (24.5%)

Differentiation

 Well

16 (50.0%)

16 (50.0%)

0.188

13 (40.6%)

19 (59.4%)

0.077

15 (46.9%)

17 (53.1%)

0.022

 Moderate

13 (31.7%)

28 (68.3%)

14 (34.1%)

27 (65.9%)

24 (58.5%)

17 (41.5%)

 Poor

15 (31.9%)

32 (68.1%)

27 (57.4%)

20 (42.6%)

36 (76.6%)

11 (23.4%)

Pleural invasion

 Negative

39 (36.4%)

68 (63.6%)

0.887

47 (43.9%)

60 (56.1%)

0.497

66 (61.7%)

41 (38.3%)

0.596

 Positive

5 (38.5%)

8 (61.5%)

7 (53.8%)

6 (46.2%)

9 (69.2%)

4 (30.8%)

Pathological stage

 Stage I

20 (54.1%)

17 (45.9%)

0.025

11 (29.7%)

26 (70.3%)

<0.001

18 (48.6%)

19 (51.4%)

0.017

 Stage II

15 (31.9%)

32 (68.1%)

17 (36.2%)

30 (63.8%)

28 (59.6%)

19 (40.4%)

 Stage III

9 (25.0%)

27 (75.0%)

26 (72.2%)

10 (27.8%)

29 (80.6%)

7 (19.4%)